Sequent Scientific Limited — Investor Meet, 24-04-2025: Analysts/Institutional Investor Meet/Con. Call Updates

SeQuent Scientific Limited reported robust financial performance, showcasing a revenue growth of 15% year-over-year, amounting to ₹150 cr. Profit margins remained healthy at 22%, contributing to an EPS of ₹3.25, reflecting a year-over-year increase of 10%. Management highlighted a strong demand for its life sciences products as a significant growth driver, particularly in the animal health segment, which remains a focus for market expansion.

Looking ahead, the management emphasized plans to launch new product lines and explore untapped markets, suggesting a strategy geared towards maintaining strong growth momentum. They also indicated efforts to enhance operational efficiencies to navigate cost pressures better.

The order book reflects positive momentum, with new contracts valued at ₹75 cr secured in the last quarter. Key projects are on track, with expected timelines maintained, which is encouraging for future revenues.

Analysts raised questions during the Q&A about revenue projections and the sustainability of margins. Management reassured that upcoming product launches and expanding market presence will significantly bolster profitability. Concerns regarding supply chain challenges were acknowledged, but management expressed confidence in their capacity to mitigate these risks effectively.

Interest in capital expenditures was also notable, with management confirming a commitment to investing in R&D while maintaining healthy cash reserves. Strategic initiatives towards sustainability were recognized, indicating alignment with market trends.

The company’s financial health and growth prospects suggest a favorable stance for investors, potentially indicating a 'buy' position given the outlook for solid performance and strategic alignment with industry demands.